Analysis of the impact of MDD (Medical Devices Directive) review amendments
This article was originally published in Clinica
Executive Summary
This week has seen the approval by the European Parliament of amendments to the European Commission's proposed review of the Medical Devices Directive and Active Implantable Medical Device Directive. Mika Reinikainen, vice-president of Quintiles Consulting, reports on the main amendments and their implications for the medical devices industry
You may also be interested in...
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials
Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.